Share on LinkedInShare on LinkedIn

ARTICLE · 20 JANUARY 2023

PTAB Institutes Mylan's Two EYLEA (Aflibercept) IPRs

As we previously reported, Mylan recently filed three IPR petitions challenging claims of Regeneron patents directed to treating angiogenic eye disorders with aflibercept...

United StatesIntellectual Property

As we previously reported, Mylan recently filed three IPR petitions challenging claims of Regeneron patents directed to treating angiogenic eye disorders with aflibercept, the active ingredient in Regeneron's Eylea product—IPR2022-01225 (challenging U.S. Patent No. 10,130,681), IPR2022-01226 (challenging U.S. Patent No. 10,888,601), and IPR2023-00099 (challenging U.S. Patent No. 10,857,205). This week, the PTAB granted institution on two of these IPR petitions. The PTAB concluded that there is a reasonable likelihood that at least challenged claim 1 of the '681 patent (IPR2022-01225) and at least challenged claim 34 of the '601 patent (IPR2022-01226) are unpatentable as being anticipated by the same prior art publication. The institution decision on the '205 patent (IPR2023-00099) is expected in April 2023.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from